ConductScience.org, home

Paper41525014

Comparison of activated and 4-factor prothrombin complex concentrates for reversal of apixaban- and rivaroxaban-associated major bleeding.

Crawley RM and 1 other. J Thromb Thrombolysis, 2026. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Comparison of activated and 4-factor prothrombin complex concentrates for reversal of apixaban- and rivaroxaban-associated major bleeding. Papers, record 41525014. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41525014

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparison of activated and 4-factor prothrombin complex concentrates for reversal of apixaban- and rivaroxaban-associated major bleeding.
PubMed
Journal
J Thromb Thrombolysis
PubMed
Year
2026
PubMed
Publication types
Journal Article, Comparative Study
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-11-05
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Crawley RMR Monroe
2Sheikh-Taha MMarwan

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Blood Coagulation FactorsMajor topic
PyridonesMajor topic
RivaroxabanMajor topic
HemorrhageMajor topic
PyrazolesMajor topic
Factor Xa InhibitorsMajor topic
Humans
Female
Male
Retrospective Studies
Aged
Middle Aged

Source PubMed

Download CSV of topics

References20

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128835439Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.Blood2017https://conductscience.org/library/papers/28835439PubMed
216630353Thrombin generation by activated factor VII on platelet activated by different agonists. Extending the cell-based model of hemostasis.Thromb J2006https://conductscience.org/library/papers/16630353PubMed
324529498Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.Thromb Res2014https://conductscience.org/library/papers/24529498PubMed
432264698Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.Circulation2020https://conductscience.org/library/papers/32264698PubMed
524391389Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy.P T2013https://conductscience.org/library/papers/24391389PubMed
611434702A cell-based model of hemostasis.Thromb Haemost2001https://conductscience.org/library/papers/11434702PubMed
738749032Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.N Engl J Med2024https://conductscience.org/library/papers/38749032PubMed
832500220Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.J Thromb Thrombolysis2021https://conductscience.org/library/papers/32500220PubMed
927573206Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.N Engl J Med2016https://conductscience.org/library/papers/27573206PubMed
10355790342022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association.Stroke2022https://conductscience.org/library/papers/35579034PubMed
1137063756Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing.Res Pract Thromb Haemost2023https://conductscience.org/library/papers/37063756PubMed
1226391431Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH.J Thromb Haemost2016https://conductscience.org/library/papers/26391431PubMed
1334060371Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors-An In Vitro Study.Clin Appl Thromb Hemost2021https://conductscience.org/library/papers/34060371PubMed
14326806462020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee.J Am Coll Cardiol2020https://conductscience.org/library/papers/32680646PubMed
1511382723Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects.Circulation2001https://conductscience.org/library/papers/11382723PubMed
1630046673The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro.Res Pract Thromb Haemost2017https://conductscience.org/library/papers/30046673PubMed
1730476716Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants.Thromb Res2019https://conductscience.org/library/papers/30476716PubMed
1824315724Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.Lancet2014https://conductscience.org/library/papers/24315724PubMed
1915842354Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.J Thromb Haemost2005https://conductscience.org/library/papers/15842354PubMed
2028239301The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor.Thromb J2017https://conductscience.org/library/papers/28239301PubMed

Download CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42026420Personalised Antithrombotic Strategies in Diverse Clinical Populations.J Thromb Thrombolysis2026https://conductscience.org/library/papers/42026420PubMed
41976898Anticoagulation Stewardship Program in the DOAC Era.J Clin Med2026https://conductscience.org/library/papers/41976898PubMed
41975035Apixaban Overdose with Massive Bleeding and Anti-Xa Levels.J Med Toxicol2026https://conductscience.org/library/papers/41975035PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
F72155PubTator's text mininghttps://conductscience.org/library/genes/2155

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41525014

GET https://conductscience.org/api/papers/v1/41525014/authors